Clinical trial
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
NCT00446446 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00446446 |
|---|---|
| Title | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) |
| Official title | Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Carcinoma, Head and Neck Cancer, Metastases, Metastatic Cancer, Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, Oncology, Squamous Cell Carcinoma, Tumors |
| Intervention type | Drug |
| Interventions | Panitumumab |
| Enrollment | 52 |
| Start date | Oct 30, 2007 |
| Primary completion | Dec 15, 2010 |
| Completion | Nov 29, 2017 |
| First posted | Mar 12, 2007 |
| Last update posted | Oct 5, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: